For UK medical/trade/consumer media only: The National Institute for Health and Care Excellence issues positive Appraisal Consultation Document for Eisai’s Kisplyx® (lenvatinib) in combination with MSD’s Keytruda® (pembrolizumab) for first-line treatment of intermediate and poor risk advanced renal cell carcinoma
For UK medical/trade/consumer media only: Scottish Medicines Consortium recommends combination of Kisplyx® (lenvatinib) plus Keytruda® (pembrolizumab) for first-line treatment of advanced renal cell carcinoma
For European medical/trade media only: Eisai and Merck receive simultaneous positive CHMP Opinions for Lenvima® (lenvatinib) plus Keytruda® (pembrolizumab) in advanced endometrial carcinoma and Kisplyx® (lenvatinib) plus Keytruda® (pembrolizumab) in advanced renal cell carcinoma
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
Click 'cancel' to return to Eisai's site or 'continue' to proceed.
You are now leaving eisai.eu
You have selected a link that will take you to another Eisai website.
Click ‘cancel’ to return to eisai.eu or ‘continue’ to proceed.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.